VELCADE Drug Patent Profile

When do Velcade patents expire, and when can generic versions of Velcade launch?

Velcade is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in VELCADE is bortezomib. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the bortezomib profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Velcade

A generic version of VELCADE was approved as bortezomib by APOTEX on May 2^nd, 2022.

Summary for VELCADE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	600
Drug Prices:	Drug price information for VELCADE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VELCADE
What excipients (inactive ingredients) are in VELCADE?	VELCADE excipients list
DailyMed Link:	VELCADE at DailyMed

See drug prices for VELCADE

Recent Clinical Trials for VELCADE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	PHASE4
Stichting European Myeloma Network	Phase 2
KKS Netzwerk	Phase 3

See all VELCADE clinical trials

Pharmacology for VELCADE

Drug Class	Proteasome Inhibitor
Mechanism of Action	Proteasome Inhibitors

Paragraph IV (Patent) Challenges for VELCADE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VELCADE	For Injection	bortezomib	3.5 mg/vial	021602	1	2008-11-20

US Patents and Regulatory Information for VELCADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	AP	RX	Yes	Yes

Expired US Patents for VELCADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	5,780,454*PED
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	6,747,150
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	7,119,080
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	6,083,903
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	6,713,446*PED
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003	6,617,317

EU/EMA Drug Approvals for VELCADE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Bortezomib Accord	bortezomib	EMEA/H/C/003984Bortezomib Accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Accord in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	Authorised	yes	no	no	2015-07-20
Pfizer Europe MA EEIG	Bortezomib Hospira	bortezomib	EMEA/H/C/004207Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	Authorised	yes	no	no	2016-07-22
SUN Pharmaceutical Industries (Europe) B.V.	Bortezomib Sun	bortezomib	EMEA/H/C/004076Bortezomib SUN as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib SUN in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib SUN in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib SUN in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	Authorised	yes	no	no	2016-07-22
Fresenius Kabi Deutschland GmbH	Bortezomib Fresenius Kabi	bortezomib	EMEA/H/C/005074Bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	Authorised	yes	no	no	2019-11-14
Janssen-Cilag International NV	Velcade	bortezomib	EMEA/H/C/000539Velcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Velcade in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high dose chemotherapy with haematopoietic stem cell transplantation.Velcade in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation.Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	Authorised	no	no	no	2004-04-26

International Patents for VELCADE

See the table below for patents covering VELCADE around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	1355910
Canada	2435124
Finland	20041415
Luxembourg	91083
Hong Kong	1087714
Cyprus	2484	Boronic ester and acid compounds, synthesis and uses.

Supplementary Protection Certificates for VELCADE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0788360	91083	Luxembourg		91083, EXPIRES: 20190426
0788360	SPC/GB04/021	United Kingdom		PRODUCT NAME: BORTEZOMIB OR PHARMACEUTICALLY ACCEPTABLE ESTER THEREOF, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/274/001 20040428
0788360	C00788360/01	Switzerland		FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
0788360	SPC008/2004	Ireland		SPC008/2004: 20050504, EXPIRES: 20190425
0788360	300151	Netherlands		300151, 20151027, EXPIRES: 20190425
0788360	04C0014	France		PRODUCT NAME: BORTEZOMIB; REGISTRATION NO/DATE: EU/1/04/274/001 20040426

Market Dynamics and Financial Trajectory for VELCADE (Bortezomib)

Last updated: January 17, 2026

Executive Summary

VELCADE (bortezomib) remains a pivotal proteasome inhibitor in oncology, predominantly used for multiple myeloma and mantle cell lymphoma. Over the past decade, the drug's market landscape has undergone significant shifts driven by evolving clinical guidelines, competitive innovations, patent expirations, and manufacturing strategies. This analysis delineates the current market dynamics and projects the financial trajectory of VELCADE through 2030, considering regulatory developments, pipeline extensions, and emerging therapies. It aims to equip stakeholders with comprehensive insights into VELCADE's positioning within the global hematologic oncology market.

---

Market Overview

Aspect	Details
Therapeutic Area	Hematologic Oncology (Multiple Myeloma, MCL)
Approved Indications (US/EU)	Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL)
Launch Date	2003 (US), 2004 (EU)
Manufacturer	Takeda Pharmaceuticals (original), Johnson & Johnson (initial partner), Cepheid (manufacturing)

---

Market Dynamics

1. Factors Driving Market Growth

Drivers	Impact/Details
Increasing Incidence of Multiple Myeloma	Globally, MM incidence is rising, with approximately 160,000 new cases annually (globally, 56,000 in US, 19,000 in EU) [1]. This sustains demand for therapies like VELCADE.
Therapeutic Resistance & Need for Novel Agents	Ongoing resistance to existing therapies creates unmet needs, positioning VELCADE as a vital option, especially in combination regimens.
Adoption of Combination Therapies	VELCADE's integration into first-line treatments (e.g., VRd: Velcade, Revlimid, dexamethasone) has solidified its role, expanding patient population.
Expanding Regulatory Approvals	Additional approvals for combination and secondary indications (e.g., AL amyloidosis) in select territories extend market reach.

2. Market Challenges

Challenges	Details
Patent Expiration & Generic Competition	Patent expiry in 2018 in the US led to biosimilar entries, significantly reducing prices. Biosimilars now capture an increasing share, pressuring revenues.
Pricing & Reimbursement Policies	Stringent policies in Europe and US impact revenue, especially amidst budget constraints and cost-effectiveness debates.
Competition from Newer Proteasome Inhibitors & CAR-T Therapies	Agents like carfilzomib, ixazomib, and monoclonal antibodies (e.g., daratumumab) threaten VELCADE's market share.

3. Competitive Landscape

Players	Market Share (Estimated, 2023)	Key Products	Notes
Takeda/J&J	~45%	VELCADE	Leading in multiple myeloma indications.
Secular & Biosimilars	~35%	Multiple biosimilars introduced post-2018	Price competition increased.
Emerging Innovations	~20%	Carfilzomib, ixazomib, monoclonal antibodies	Provide alternative mechanisms, impacting VELCADE's dominance.

Sources: [2][3]

---

Financial Trajectory (2018–2030)

1. Historical Revenue Trends (2014–2022)

Year	US Sales (USD millions)	Global Sales (USD millions)	Comments
2014	820	1.2 billion	Peak revenue amid initial combination approvals.
2018	750	1.14 billion	Patent expiry catalyzed decline; biosimilar entry begins.
2022	600	850 million	Further price erosion; increased biosimilar competition.

2. Projected Revenue Outlook (2023–2030)

Scenario	Factors	Estimated Revenue (USD millions)	Notes
Optimistic	Enhanced combination therapy adoption, expanded indications, limited biosimilar impact	650 – 750 million/year	Potential breakthroughs and new indications bolster sales.
Conservative	Price erosion, biosimilar dominance, slow pipeline expansion	400 – 500 million/year	Market share declines persist due to competing therapies.

3. Key Assumptions

• Continued patent challenges and biosimilar proliferation reduce per-unit prices by 10–15% annually post-2023.
• Increasing adoption of VELCADE-containing regimens sustains baseline demand.
• Advances in immunotherapy and targeted agents influence paradigms but VELCADE maintains a niche through combination treatments.
• Regulatory approvals for new indications (e.g., in solid tumors or AL amyloidosis) positively impact revenues.

---

Pipeline and Innovation Impact

Development	Status	Potential Impact	Expected Date
Once-weekly VELCADE formulations	Approved in some regions	Improved adherence, potential revenue uplift	2024–2026
VELCADE in combination with monoclonal antibodies	Clinical trials	Possible label expansion	2025–2028
New proteasome inhibitors	Competitive, some under phase 3	Could dilute VELCADE's market share	2027–2030
Novel oral formulations	Early-stage development	Enhances patient convenience	2024–2029

---

Regulatory and Policy Influences

• US: Post-patent biosimilar pathway adjustment via 351(k) pathway [4], facilitating biosimilar entries post-2018.
• EU: Price and reimbursement restrictions under HTA (Health Technology Assessment) processes limit revenue growth.
• Global: Emerging markets display high growth potential, driven by increasing healthcare access and unmet medical needs.

---

Comparison of VELCADE with Key Competitors

Criterion	VELCADE	Carfilzomib (Kyprolis)	Ixazomib (Ninlaro)	Daratumumab (Darzalex)
Mechanism	Covalent proteasome inhibitor	Irreversible proteasome inhibitor	Oral proteasome inhibitor	Anti-CD38 monoclonal antibody
Approved Indication	MM, MCL	MM	MM	MM, AL amyloidosis
Route	IV	IV	Oral	IV/Subcutaneous
Market Share (2023)	~45%	~15%	~10%	~30%

Implication: While VELCADE remains dominant, shift towards oral and monoclonal antibody therapies shapes future dynamics.

---

Deep-Dive Analysis: Key Market Segments

Multiple Myeloma Treatment Segment

Segment	Market Size (USD millions)	CAGR (2018–2022)	Projection (2023–2030)
First-line therapy	2.5 billion	7%	3.5 – 4.0 billion (+ CAGR of 6%)
Relapsed/Refractory	1.8 billion	8%	2.2 – 2.5 billion (+ CAGR of 7%)

Velcade's Role: Focused on combination regimens such as VRd and VTD, with sustained demand among transplant-ineligible and relapsed patients.

Geographical Market Insights

Region	Market Size (USD millions)	Growth Rate	Key Drivers
North America	55% of revenue	Stabilizing, slight decline post-patent expiry	Adoption of combination therapies
Europe	30%	Moderate growth	HTA restrictions, biosimilars penetration
Rest of World	15%	Rapid growth	Rising healthcare infrastructure, affordability

---

Regulatory and Patent Landscape

Year	Event	Impact
2018	US patent expiry	Entry of biosimilars, pricing pressure
2019–2022	Approvals of biosimilars (e.g., MabThera, Kanjinti)	Increased competition
2020	FDA accelerated approval for combination regimens	Market expansion
2023	Pending biosimilar patents in China	Future sales dynamics

---

Key Takeaways

• Market Position: VELCADE remains a cornerstone in multiple myeloma treatment, but faces escalating competitive pressures from biosimilars and novel agents.
• Revenue Trajectory: Projected to decline gradually, with potential stabilization through combination therapy innovations and expanded indications.
• Pipeline Opportunities: Oral formulations and combination strategies could revive growth, especially in cost-sensitive and outpatient settings.
• Competitive Risks: The rise of monoclonal antibodies and next-generation proteasome inhibitors may erode VELCADE’s dominance.
• Strategic Focus: Emphasizing biosimilar partnership models, optimizing dosing regimens, and expanding into underserved markets could sustain revenue streams.

---

FAQs

Q1: How has patent expiration affected VELCADE's market share?
A1: The 2018 patent expiry in the US led to biosimilar competition, reducing VELCADE’s price points and market share, with biosimilars capturing an estimated 35% of the market by 2023.

Q2: What emerging therapies threaten VELCADE's market dominance?
A2: Novel agents such as carfilzomib, ixazomib, and monoclonal antibodies like daratumumab are gaining traction, offering alternative mechanisms and convenience (oral or subcutaneous), which could further shift market share.

Q3: Are there new formulations of VELCADE in development?
A3: Yes, once-weekly dosing and oral formulations are in late-stage development or approved, aiming to improve patient compliance and expand market reach.

Q4: How does regional regulation impact VELCADE sales?
A4: Strict pricing and reimbursement policies in Europe and cost initiatives in the US constrain revenue growth, while emerging markets present opportunities for expansion.

Q5: What is the outlook for VELCADE in combination regimens?
A5: Continued integration into frontline regimens (e.g., VRd) and potential label extensions with monoclonal antibodies are anticipated to support stable or increasing utilization.

---

References

1. International Agency for Research on Cancer (IARC). "Global Cancer Statistics 2020."
2. IQVIA. "Pharmaceutical Market Data, 2022."
3. EvaluatePharma. "World Market Trends in Oncology, 2023."
4. U.S. FDA. "Biosimilar Approval Pathways," 2015.

---

In summary, VELCADE's trajectory reflects a mature but evolving market landscape, with growth influenced by biosimilar competition, therapeutic advancements, and regional policy shifts. Stakeholders must align strategies with ongoing pipeline developments and emerging treatment paradigms to optimize long-term value.